Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Wet Macular Degeneration
100%
Ranibizumab
79%
Stereotactic Radiotherapy
60%
Brachytherapy
40%
Visual Acuity
32%
Ocriplasmin
30%
Randomized Controlled Trial
29%
Vasculotropin
25%
Age Related Macular Degeneration
22%
Vitrectomy
21%
Randomized Clinical Trial
20%
Macular Hole
20%
Controlled Clinical Trial
20%
Vitreous Hemorrhage
20%
Diabetes Mellitus
20%
Placebo
20%
Ophthalmic Surgical Instrument
20%
Pars Plana Vitrectomy
19%
Best Corrected Visual Acuity
16%
Adverse Event
14%
Monotherapy
11%
Diabetic Retinopathy
9%
Intravitreal Administration
9%
Intention-to-Treat Analysis
7%
Farnsworth-Munsell 100 Hue Test
6%
Injection
6%
Aflibercept
6%
Visual Impairment
5%
Retinal Detachment
5%
Vitreous
5%
Systematic Review
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ranibizumab
60%
Wet Macular Degeneration
40%
Ocriplasmin
30%
Randomized Controlled Trial
25%
Aflibercept
23%
Bevacizumab
20%
Retina Macula Hole
20%
Randomized Clinical Trial
20%
Vasculotropin
15%
Buffer
13%
Adverse Event
10%
Monotherapy
8%
Diabetic Retinopathy
8%
Retina Detachment
5%
Visual Impairment
5%
Nursing and Health Professions
Wet Macular Degeneration
40%
Brachytherapy
20%
Ocriplasmin
20%
Radiotherapy
20%
Ranibizumab
15%
Confidence Interval
12%
Best Corrected Visual Acuity
10%
Vasculotropin
7%
Injection
6%
Monotherapy
5%